163 related articles for article (PubMed ID: 32878571)
1. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
[TBL] [Abstract][Full Text] [Related]
2. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
3. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
[TBL] [Abstract][Full Text] [Related]
4. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Brogan AJ; Davis AE; Goodwin B
PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
[TBL] [Abstract][Full Text] [Related]
5. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
[TBL] [Abstract][Full Text] [Related]
7. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Lee SA; Telwatte S; Hatano H; Kashuba ADM; Cottrell ML; Hoh R; Liegler TJ; Stephenson S; Somsouk M; Hunt PW; Deeks SG; Yukl S; Savic RM
J Acquir Immune Defic Syndr; 2020 Apr; 83(5):530-537. PubMed ID: 32168200
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
[TBL] [Abstract][Full Text] [Related]
10. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
11. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
McComsey GA; Moser C; Currier J; Ribaudo HJ; Paczuski P; Dubé MP; Kelesidis T; Rothenberg J; Stein JH; Brown TT
Clin Infect Dis; 2016 Apr; 62(7):853-62. PubMed ID: 26797215
[TBL] [Abstract][Full Text] [Related]
12. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort.
d'Arminio Monforte A; Lorenzini P; Cozzi-Lepri A; Mussini C; Castagna A; Baldelli F; Puoti M; Vichi F; Maddaloni A; Lo Caputo S; Gianotti N; Antinori A;
HIV Clin Trials; 2018 Apr; 19(2):52-60. PubMed ID: 29493419
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
Jabłonowska E; Pulik P; Kalinowska A; Gąsiorowski J; Parczewski M; Bociąga-Jasik M; Pulik Ł; Siwak E; Wójcik K
J Med Virol; 2017 Dec; 89(12):2122-2129. PubMed ID: 28390164
[TBL] [Abstract][Full Text] [Related]
14. Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina.
Rombini F; Cecchini DM; Ballivian J; Huberman M; Urueña A; Cassetti I
Rev Esp Quimioter; 2021 Feb; 34(1):56-60. PubMed ID: 33267555
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
[TBL] [Abstract][Full Text] [Related]
17. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS
Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466
[TBL] [Abstract][Full Text] [Related]
19. Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.
Jao J; Balmert LC; Sun S; McComsey GA; Brown TT; Tien PC; Currier JS; Stein JH; Qiu Y; LeRoith D; Kurland IJ
J Clin Endocrinol Metab; 2022 Jan; 107(1):119-135. PubMed ID: 34498048
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
